Skip to main content

Table 2 Knowledge, perception and opinions towards the generic (2011)

From: Perception and attitude of Korean physicians towards generic drugs

Variables   Answer N %
Knowledge BE criteriaa Not informed at all 12 3.3
A little informed 53 14.7
Moderately informed 228 63.2
Completely informed 68 18.8
Reliability BE results Not at all confident 3 0.8
Not very confident 79 21.9
Neutral 186 51.6
Very confident 90 24.9
Completely confident 3 0.9
Perceptions Safety and effectiveness compared to original Non-equivalent 192 53.2
Neutral 106 29.3
Equivalent 63 17.5
Main reasons for the negative recognition Clinical experience 116 32
Confidence limit in BE test 94 26
Confidence limit in generic 94 26
Effect limit 32 9
Evidence limit 11 3
Others (minor opinion)* 14 4
Price Low price 20 5.5
Accurate price 109 30.2
Over price 232 64.3
Opinions Reasonable price of generic Same price as original 11 3
80% of original 93 25.8
70% of original 95 26.3
60% of original 85 23.5
Less than 50% of original 77 21.3
Factors associated with the generic substitution
(subjective response)
Same equivalent effects and safety as the original 316 87.5
Confidence of the pharmaceutical company 34 9.4
Drug price 8 2.2
Pharmaceutical marketing activity 2 0.6
Hospital policy 1 0.3
Factors to improve the generic prescription
(multiple response b)
Quality maintenance of generic 261 32.6
BE confidence recovery 216 26.9
Disclosure of the BE results 193 24
Price cut 88 10.9
Incentive policy 41 5
Others 5 0.6
Prescription behavior If generic quality would be improved Switch to the generic 305 84.4
No change 53 14.7
Switch to the original 3 0.9
  1. The BE test states that two treatments are not different from one another if the 90% confidence interval of the ratio of a log-transformed exposure measure (AUC and/or Cmax) falls completely within the range 80-125%
  2. aBE criteria in south Korea MFDA
  3. bRespondents could choose several options